We are on a mission to progress the development of a new pharmaceutical solution that can effectively address life-threatening and disabling hemorrhagic conditions.
Hemostatics Pharmaceuticals S.L. is an emerging biotechnology company specialising in the development of a novel antifibrinolytic agent. The Company was created in August 2020 by a highly experienced team who established a strategic partnership and exclusive Licensing for the technology with the “Fundación para la Investigación Médica Aplicada” (FIMA), a not-for-profit foundation managing the “Centro de Investigación Médica Aplicada” (CIMA, University of Navarra), the biomedical research center of the “Clinica Universidad de Navarra”, based in Pamplona, Spain.
The Hemostatics Team is actively working to complete the preclinical development plan and be ready to transition to Phase 1, while in parallel securing funding.
Our vision is to substantially contribute to an improved healthcare with better clinical outcomes and quality of life for people dealing with major bleeding events.
Want To Start Investing With Us?
Investing in the novel biopharmaceutical technology of Hemostatics can help accelerating the development of innovative solutions addressing potentially life-threatening hemorrhagic conditions.